{"id":2850,"date":"2026-09-02T07:00:00","date_gmt":"2026-09-02T11:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2850"},"modified":"2026-09-02T19:51:50","modified_gmt":"2026-09-02T23:51:50","slug":"uniqure-submits-amt-130-for-u-s-and-u-k-review","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2850","title":{"rendered":"uniQure Submits AMT-130 for U.S. and U.K. Review"},"content":{"rendered":"

Company:<\/strong> uniQure · Drug:<\/strong> Ifezuntirgene Inilparvovec (AMT-130) · Indication:<\/strong> Huntington’s Disease · Regulatory Action:<\/strong> BLA (U.S.) + MAA (U.K.) Submitted · Date:<\/strong> September 2, 2026<\/p>\n

\"uniQure<\/p>\n

Summary<\/h4>\n

uniQure submitted a Biologics License Application to the U.S. Food and Drug Administration seeking accelerated approval of ifezuntirgene inilparvovec, formerly AMT-130, for Huntington’s disease and separately submitted a Marketing Authorisation Application to the U.K. Medicines and Healthcare products Regulatory Agency. The company requested U.S. Priority Review. Neither application has been accepted for review or validated, and no approval decision has been made.<\/p>\n

What Happened<\/h4>\n

Both filings rely on the previously disclosed three-year analysis from uniQure’s Phase I\/II program, compared with propensity score-matched external controls from Enroll-HD. In the high-dose analysis, 12 treated patients with 36-month follow-up had a mean composite Unified Huntington’s Disease Rating Scale change of -0.38 versus -1.52 in the external control, which the company described as 75% slower progression. The filings also include safety, biomarker and manufacturing information that is not fully public. The U.S. application requests accelerated approval after a June Type B meeting in which FDA said the three-year analysis could serve as the primary basis of a BLA and sought alignment on a confirmatory study. Priority Review, if granted after the 60-day filing review, would target a six-month review cycle. The company plans to disclose four-year data before the end of the third quarter.<\/p>\n

Deep Analysis<\/h4>\n

Submission in both jurisdictions moves AMT-130 from clinical development into formal regulatory evaluation and preserves a potential first disease-modifying approval in Huntington’s disease. FDA’s prior willingness to accept the external-control analysis as the primary BLA basis supports the path, though acceptance for filing, review designation and approval remain separate decisions, and FDA may request more information or conclude the evidence is insufficient. The effect size and concordant functional measures may indicate clinically meaningful slowing, but the pivotal inference rests on a very small treated cohort and a nonconcurrent external control rather than a randomized long-term comparison. Differences in patient selection, assessment, follow-up and unmeasured confounding could exaggerate or attenuate the apparent effect, and direct neurosurgical delivery also concentrates procedural, manufacturing and center-capacity risk.<\/p>\n

Company and Product Background<\/h4>\n

uniQure develops adeno-associated virus gene therapies for severe genetic and neurologic diseases. Ifezuntirgene inilparvovec uses an AAV5 vector carrying an engineered microRNA intended to reduce huntingtin messenger RNA, including transcripts that generate the toxic exon-1 huntingtin fragment. A single dose is delivered by MRI-guided, convection-enhanced stereotactic infusion into the caudate and putamen. Huntington’s disease is an autosomal-dominant neurodegenerative disorder caused by an expanded CAG repeat in HTT; progressive motor, cognitive and psychiatric impairment results from toxic mutant huntingtin biology and neuronal loss. Available therapies manage symptoms but do not have an approved indication for slowing the underlying disease. The Phase I\/II program includes a 26-patient U.S. randomized sham-controlled first year, a 13-patient European open-label study, a 12-patient immunosuppression cohort and a six-patient lower-striatal-volume cohort; long-term efficacy comparisons use external controls.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Regulatory Filings<\/td>\nBLA (FDA) + MAA (U.K. MHRA) submitted September 2, 2026<\/td>\n<\/tr>\n
Review Request<\/td>\nU.S. accelerated approval + Priority Review requested<\/td>\n<\/tr>\n
Evidence Basis<\/td>\n3-year Phase I\/II data vs. propensity-matched Enroll-HD external control<\/td>\n<\/tr>\n
Reported Effect<\/td>\nMean cUHDRS change -0.38 vs. -1.52 (75% slower progression, per company)<\/td>\n<\/tr>\n
Next Catalyst<\/td>\n4-year data disclosure planned before end of Q3 2026<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> Dual regulatory submissions, combined with FDA’s prior acceptance of the external-control analysis as a primary BLA basis, move a potential first disease-modifying Huntington’s therapy from development into formal review with a defined accelerated-approval pathway.<\/p>\n

Bear case:<\/strong> The pivotal evidence rests on only 12 high-dose treated patients with 36-month follow-up compared against a nonconcurrent external natural-history control, leaving the causal magnitude and durability of the apparent slowing unconfirmed pending a randomized confirmatory study.<\/p>\n

InSilens Take<\/h4>\n

The dual submission is a high-importance positive regulatory milestone, not an approval. It is more consequential than a planned filing because the dossiers have now been delivered, but the central evidentiary tension is unchanged: a potentially large and durable signal is being inferred from few treated patients against an external natural-history control. The next decisive evidence is agency acceptance and the four-year analysis, followed by the design and execution of a confirmatory study capable of testing whether the apparent disease slowing is causal and durable.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 5\/5 · Direction:<\/strong> Positive · Confidence:<\/strong> High on facts, Moderate on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

uniQure submitted a Biologics License Application to the U.S. Food and Drug Administration seeking accelerated approval of ifezuntirgene inilparvovec, formerly AMT-130, for Huntington’s disease and separately submitted a Marketing Authorisation Application to the U.K….<\/p>\n","protected":false},"author":1,"featured_media":2851,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[516,515,26,514],"class_list":["post-2850","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-aav-gene-therapy","tag-amt-130","tag-huntingtons-disease","tag-uniqure"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2850"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2850\/revisions"}],"predecessor-version":[{"id":2856,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2850\/revisions\/2856"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2851"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}